Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
fMRI Biomarker of Opioid Antagonism in Adolescents With Eating Disorders
NCT05509257Phase 1Active, not recruiting
- Sponsor
- Children's Mercy Kansas City
- Start
- Sep 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of naltrexone in eating disorders (2 arms), sponsored by Children's Mercy Kansas City. Primary endpoint: Response at 2 hours. Started Sep 2022; status: active, not recruiting.
02
Drugs
naltrexone
03
Conditions
eating disorders
Beyond the preview
Go deeper on NCT05509257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05509257.